3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
2
Neoplasms
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroectodermal Tumors, Primitive
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
antineoplaston AS 2-1
4
antineoplaston A10
4
Cyclophosphamide
4
Cisplatin
4
Temozolomide
3
Radiotherapy
3
dactolisib
2
Vincristine
2
Filgrastim
2
Everolimus
2
Etoposide
2
Bevacizumab
2
spartalizumab
1
sargramostim
1
pasireotide
1
ganitumab
1
gallium Ga 68 dotatate
1
fosbretabulin
1
cixutumumab
1
belzutifan
1
aldesleukin
1
Topotecan
1
Thiotepa
1
TH 302
1
Sunitinib
1
Standard of Care
1
Pregabalin
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neuroectodermal Tumors, Primitive
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts